<DOC>
	<DOCNO>NCT00049777</DOCNO>
	<brief_summary>The purpose study evaluate relative efficacy safety prophylactic heparin co-administration drotrecogin alfa ( activate ) infusion treatment severe sepsis adult .</brief_summary>
	<brief_title>A Trial Heparin Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa ( Activated )</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Drotrecogin alfa activate</mesh_term>
	<mesh_term>Calcium heparin</mesh_term>
	<mesh_term>Protein C</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin</mesh_term>
	<criteria>Inclusion Criteria Adults great equal 18 year age Receiving inpatient treatment severe sepsis Indicated treatment Drotrecogin Alfa ( Activated ) approve label country patient enrol Exclusion Criteria Contraindicated heparin treatment Require high dose heparin define trial Have acute chronic renal failure estimate creatinine clearance le 30mL/min Weigh 135 kg ( 297 pound ) Are expect survive 28 day give medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>